The device, which allows coronary valve replacement without open-heart surgery, can now be purchased directly from the company. Sales between $20 million and $25 million are expected in the first three months, and sales between $150 million to $250 million are expected in the first year.
Related Articles on Medical Devices:
Medical Device Recalls Continue to Increase in Third Quarter
FDA Opens Comment Period for Medical Device Labeling
Report: Growth in Medical Device Adverse Events Outpaces Industry Growth
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.